Antitumor agent-145

CAS: 2983120-65-4 F: C44H34IrN5OS W: 873.06

Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which

Contact QiTai

This product is for research use only, not for human use. We do not sell to patients.

Bioactivity	Antitumor agent-145 (Compound Ir5) is a tumor inhibitor with remarkable fluorescence and mitochondrial targeting, which exerts anti-cancer effects by inducing necroptosis and activating the necroptosis-related immune response[1].
Invitro	Antitumor agent-145 (Compound Ir5) (48h) 对 BEL-7402/DDP 细胞的 IC50 值为 0.49 μM，阻力系数(RF) 为 1.04。Antitumor agent-145 无明显细胞毒性[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Antitumor agent-145 相关抗体:
In Vivo	Antitumor agent-145 (Compound Ir5) (1.5/3.0 mg/kg，静脉注射，每隔一天，共21天) 能显著降低 BALB/c 小鼠中的肿瘤体积。Antitumor agent-145 在小鼠模型中不会引起明显的肝肾功能障碍[1].Antitumor agent-145 (1.5/3.0 mg/kg，静脉注射，每隔一天，共21天) 在 BEL-7402/DDP 肿瘤异种移植模型中能显著抑制CDDP耐药肿瘤的生长和转移，不导致明显组织损伤[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model:
CAS	2983120-65-4
Formula	C44H34IrN5OS
Molar Mass	873.06
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Li, Wenjuan et al. “Designing a Mitochondria-Targeted Theranostic Cyclometalated Iridium(III) Complex: Overcoming Cisplatin Resistance and Inhibiting Tumor Metastasis through Necroptosis and Immune Response.” Journal of medicinal chemistry vol. 67,5 (2024): 3843-3859.

Adenosine N1-oxide